Precipio Ships First IV-Cell® Order to Major US Healthcare System NEW HAVEN, Conn., March 21, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) delivered its first order of IV-Cell®, the Company’s proprietary cytogenetics...

Precipio Signs First IV-Cell Customer Agreement NEW HAVEN, Conn., May 10, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that American Oncology Network (AON) of Fort Myers, Florida,...

Precipio & ADS Biotec Launch Seven Beta sites for IV-Cell™ NEW HAVEN, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), along with its partner ADS Biotec announce the launch of the beta phase...

Precipio Signs Exclusive Manufacturing Agreement for IV-Cell™ NEW HAVEN, Conn., June 04, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has entered into an exclusive subcontracting manufacturing...